Overview
TLSA market data
Price History
TLSA price chart · 1M
- O
- 1.09
- H
- 1.09
- L
- 1.06
- C
- 1.08
- Vol
- 6,335.00
- Source
- US equities market feed
- Observed
- Aug 27, 2026, 12:00 AM
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $1.09
- Previous Close
- $1.09
- Day High
- $1.09
- Day Low
- $1.06
- 52 Week High
- $1.85
- 52 Week Low
- $0.90
- 7 Day Return
- -4.44%
- 30 Day Return
- +9.69%
- 90 Day Return
- -23.76%
- 1 Year Return
- -15.35%
- Daily Notional Volume
- $6.8K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.17 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.22 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.87 – $2.35 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $133.4M · P/B 3,405.57.
Company News
Tiziana Life Sciences To Present Poster, Titled Phase 2a Trial Of Intranasal Foralumab – BANYAN, A Healey ALS MyMatch Trial, At ALS Nexus 2026Benzinga · Aug 24, 2026, 1:28 PM
Tiziana Life Sciences Announces CEO Ivor Elrifi Purchased 667,000 Common Shares At $1.00 Per Share, Raising Total Holding To 4,472,261 SharesBenzinga · Aug 4, 2026, 11:10 AM
Tiziana Life Sciences Says Imaging Results Show Neuroinflammation Reduction in Rare Neurodegenerative ConditionBenzinga · Jul 31, 2026, 5:32 PM
Tiziana Life Sciences shares are trading higher after the company announced quantitative PET imaging results from the third patient with Multiple System Atrophy in the Phase 2 clinical trial treated with intranasal foralumab to complete dosing.Benzinga · Jul 31, 2026, 1:54 PM
Tiziana Life Sciences Announces Quantitative PET Imaging Results From Third Patient With Multiple System Atrophy In Its Phase 2 Clinical Trial Treated With Intranasal Foralumab To Complete Dosing; Scans Demonstrated Reductions In Inflammatory ActivityBenzinga · Jul 31, 2026, 11:07 AM
Tiziana Life Sciences shares are trading higher after the company announced its executive chairman bought 42,357 shares.Benzinga · Jul 22, 2026, 1:05 PM
Tiziana Life Sciences Executive Chairman Gabriele Cerrone Buys 42,357 Shares At $0.99 Per Share, Bringing Total Holding To 44,814,587 Shares, 34.93% Of Issued Share CapitalBenzinga · Jul 22, 2026, 11:05 AM
Tiziana Announces Last Patient In Ongoing Phase 2a Clinical Trial Receives First Dose Of Intranasal Foralumab For Treatment Of Non-Active Secondary Progressive Multiple Sclerosis; Topline Data Expected In Late Q3/Early Q4 Of 2026Benzinga · Jun 25, 2026, 11:10 AM
Tiziana Life Sciences Says Its Executive Chairman And Founder, Gabriele Cerrone, Increases Holdings With Purchase Of 15,000 Common Shares At $1.11 Per ShareBenzinga · Jun 15, 2026, 11:15 AM